Lipocine's Oral PPD Drug LPCN 1154 Misses Phase 3 Primary Endpoint
Apr 02, 2026
Lipocine's oral postpartum depression drug LPCN 1154 failed to meet its primary endpoint in a Phase 3 trial involving 90 patients. However, a post hoc analysis showed clinically meaningful improvements in a subset of 54 patients with psychiatric history, and the drug demonstrated a favorable safety profile supporting outpatient use.